close

Agreements

Date: 2011-06-09

Type of information: Distribution agreement

Compound: Nova23041

Company: Novagali Pharma (France) Ardeo Health (USA) OCuSOFT (USA)

Therapeutic area: Ophtalmological diseases

Type agreement:

distribution

Action mechanism:

Nova23041 is a preservative-free oil-in-water emulsion resulting from Novasorb® patented technology. Based on the electrostatic attraction between the positively charged eye drop and the negatively charged ocular surface, Novasorb®’s technological platform enables the product to be spread in an optimal, uniform and comfortable way across the entire ocular surface, improves resilience time and thus reduces the number of instillations necessary with increased efficiency and optimal compliance and tolerance.

Disease:

Details:

Novagali Pharma has signed an exclusive agreement with Ardeo Health, LLC for Nova23041 its unique formulation for the treatment of dry eye symptoms in the United States and Canada with OCuSOFT, Inc. Nova23041 has been successfully marketed since 2008 under the brand name Cationorm®, a brand that belongs to Novagali Pharma. The product is already recommended by ophthalmologists in numerous countries throughout Europe, North Africa, the Middle East and Southeast Asia. Nova23041 will be marketed in the United States and Canada under the brand name Retaine® MGD™ Ophthalmic Emulsion. OCuSOFT, Inc. will become the exclusive promoter.

Financial terms:

Financial details were not disclosed.

Latest news:

Is general: Yes